A day after Amgen Inc. licensed an experimental drug from another local biotech, a drugmaker in the United Kingdom said that it has licensed one of Amgen’s own pipeline drugs to commercialize.

MedImmune, the worldwide biologics unit of AstraZeneca PLC of London, on Friday announced a licensing agreement with the Thousand Oaks company to develop an antibody called AMG 108 to treat certain inflammatory diseases.

Under the terms of the agreement, Amgen has granted MedImmune the right to develop AMG 108 worldwide outside of Japan. Amgen will get an upfront payment, development-related milestone payments and royalties upon sale of a commercial product. Other terms were not disclosed.

Amgen on Thursday said it licensed an experimental antibody-based therapy, being studied to treat autoimmune diseases, from Monrovia biotech Xencor. Antibody drugs work with body’s immune system to fight disease.

Amgen shares were up 42 cents, or less than a percent, to $56.97 in midday trading on the Nasdaq.